NEW YORK, June 6 /PRNewswire/ -- Ovid Technologies, an internationally recognized leader of electronic medical, scientific, and academic information research solutions, today announced its exclusive partnership with scientific publisher Elsevier to offer EMBiology, a new bibliographic database in the field of bioscience.
EMBiology is an essential, affordable resource for small-to-mid-sized academic institutions as well as all pharmaceutical and biotechnology companies interested in extending their biomedical coverage to pure and applied bioscience research. The database provides the most up-to-date biological research covering biochemistry, microbiology and molecular biology, genetics and biotechnology, cell and developmental biology, as well as plant and animal science, agriculture and food science, ecology and environmental science, and toxicology.
"Our analysis indicated a strong market for affordable biosciences information, covering both laboratory and field sciences. By working in partnership with Elsevier, we can offer unsurpassed access to the breadth and depth of global biological science literature," said Scott MacFarland, Vice President of Content Product Management at Ovid. "Our goal is to provide our customers with a selection of complementary bibliographic and full text bioscience sources to create the right mix of content to support their needs. EMBiology is a cost-effective solution for customers who require essential life sciences literature."
The EMBiology database is comprised of more than four million global bibliographic records dating back to 1980. With more than 250,000 records added annually, EMBiology offers cover to cover indexing of more than 2,800 active titles including peer-reviewed journals, trade publications and electronic-only journals. This essential A&I resource includes nearly 1,800 unique titles not covered by EMBASE, providing unique coverage of niche subject areas.
The database features two robust thesauri merged into a single file: EMTREE, Elsevier's powerful life science thesaurus, and a new Organism taxonomy of more than 500,000 terms. The Organism vocabulary is based on the taxonomies of the National Center for Biotechnology Information (NCBI) and Integrated Taxonomic Information System (ITIS), and supports searches for species names, genera and taxonomic terms at all levels, just as in EMTREE. This rich thesaurus enables sophisticated searches constructed with minimum effort to help researchers and students quickly and effectively find the answers they need.
"We're delighted to work in partnership with Ovid to bring this important biology resource to market, complementing as it does the EMBASE database that is already available on Ovid," said Chris Kluiters, Director of Bibliographic Databases, Elsevier. "We are excited to provide our resources and content to Ovid to serve bioscience professionals in a database that caters to all of their research needs."
Available on the Ovid Web Gateway platform, EMBiology is an essential complement to the breadth of high quality biosciences journals, books, and databases from Ovid.
Ovid (http://www.ovid.com) is an information solutions provider focused on offering the combination of content, tools and services that makes research smarter, faster and more effective. Ovid energizes the thinking of researchers and clinicians by developing the individualized experience each customer needs. We support Ovid Online and SilverPlatter Online customers, and provide a local solution for customers requiring offline access. Ovid is used by the world's leading colleges and universities; medical schools; academic research libraries and library consortia; hospitals and healthcare systems; pharmaceutical, engineering and biotechnology companies; HMOs and clinical practices. Ovid is an operating company of Wolters Kluwer Health (WKHealth), a division of Wolters Kluwer, a leading multinational publisher and information services company with annual sales (2004) of euro 3.3 billion and approximately 18,400 employees worldwide.
Elsevier is a world-leading publisher of scientific, technical and medical information products and services. Working in partnership with the global science and health communities, Elsevier's 7,000 employees in 74 offices worldwide publish more than 1,800 journals and 2,200 new books per year, in addition to offering a suite of innovative electronic products, such as ScienceDirect (http://www.sciencedirect.com), MD Consult (http://www.mdconsult.com), Scopus (http://www.news.scopus.com), bibliographic databases, and online reference works.
Elsevier (http://www.elsevier.com) is a global business headquartered in Amsterdam, The Netherlands and has offices worldwide. Elsevier is part of Reed Elsevier Group plc (http://www.reedelsevier.com), a world-leading publisher and information provider. Operating in the science and medical, legal, education and business-to-business sectors, Reed Elsevier provides high- quality and flexible information solutions to users, with increasing emphasis on the Internet as a means of delivery. Reed Elsevier's ticker symbols are REN (Euronext Amsterdam), REL (London Stock Exchange), RUK and ENL (New York Stock Exchange).